Contact this trialFirst, we need to learn more about you.
Opioid Antagonist
Low-Dose Naltrexone for Post-COVID Fatigue Syndrome
Recruiting2 awardsPhase 2
Vancouver, British Columbia
This trial tests low-dose naltrexone (LDN) to see if it can reduce fatigue and inflammation in people aged 19-69 who have persistent symptoms after recovering from COVID-19. LDN is a small dose of a medication usually used for addiction, which might help by calming the immune system.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service